AIM:SALV

Stock Analysis Report

Executive Summary

SalvaRx Group plc discovers and develops immune-oncology drugs.

Snowflake

Fundamentals

Solid track record and fair value.

Share Price & News

How has SalvaRx Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

SALV

0.4%

GB Biotechs

2.3%

GB Market


1 Year Return

-93.0%

SALV

26.6%

GB Biotechs

2.5%

GB Market

Return vs Industry: SALV underperformed the UK Biotechs industry which returned 26.6% over the past year.

Return vs Market: SALV underperformed the UK Market which returned 2.5% over the past year.


Shareholder returns

SALVIndustryMarket
7 Day0%0.4%2.3%
30 Day0%3.1%-1.3%
90 Day0%2.5%-1.9%
1 Year-93.0%-93.0%27.5%26.6%7.4%2.5%
3 Year-84.2%-84.2%12.3%10.4%18.8%4.3%
5 Yearn/a55.9%52.2%36.4%6.8%

Price Volatility Vs. Market

How volatile is SalvaRx Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SalvaRx Group undervalued compared to its fair value and its price relative to the market?

0.025x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate SALV's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate SALV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SALV is good value based on its PE Ratio (0x) compared to the Biotechs industry average (32.2x).

PE vs Market: SALV is good value based on its PE Ratio (0x) compared to the UK market (16.4x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SALV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SALV is good value based on its PB Ratio (0.3x) compared to the GB Biotechs industry average (1.7x).


Next Steps

Future Growth

How is SalvaRx Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SalvaRx Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has SalvaRx Group performed over the past 5 years?

103.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SALV's earnings have grown significantly by 103.5% per year over the past 5 years.

Accelerating Growth: SALV's earnings growth over the past year (6826.7%) exceeds its 5-year average (103.5% per year).

Earnings vs Industry: SALV earnings growth over the past year (6826.7%) exceeded the Biotechs industry -2.3%.


Return on Equity

High ROE: SALV's Return on Equity (1074.8%) is considered outstanding.


Return on Assets

ROA vs Industry: SALV has a higher Return on Assets than the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: SALV is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is SalvaRx Group's financial position?


Financial Position Analysis

Short Term Liabilities: SALV's short term assets (£2.1M) exceeds its short term liabilities (£1.1M)

Long Term Liabilities: SALV has no long term liabilities


Debt to Equity History and Analysis

Debt Level: SALV's debt to equity ratio (14.5%) is considered satisfactory

Reducing Debt: Insufficient data to determine if SALV's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: SALV's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if SALV's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: SALV has a low level of unsold assets or inventory.

Debt Coverage by Assets: SALV's debt is covered by short term assets (assets are 2.552310x debt).


Next Steps

Dividend

What is SalvaRx Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SALV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SALV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SALV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SALV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SALV's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of SalvaRx Group's salary, the management and board of directors tenure and is there insider trading?


CEO

SalvaRx Group has no CEO, or we have no data on them.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Denham Hervey Eke (67yo)

    CFO & Director

    • Tenure: 0.8yrs

Board Members

  • Greg Bailey (63yo)

    Non Executive Director

    • Tenure: 0yrs
  • Jim Mellon (62yo)

    Non Executive Chairman

    • Tenure: 0yrs
  • Denham Hervey Eke (67yo)

    CFO & Director

    • Tenure: 0.8yrs

Company Information

SalvaRx Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SalvaRx Group plc
  • Ticker: SALV
  • Exchange: AIM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£1.651m
  • Shares outstanding: 36.70m
  • Website: https://www.salvarx.io

Number of Employees


Location

  • SalvaRx Group plc
  • Commerce House
  • 1 Bowring Road
  • Ramsey
  • IM8 2LQ
  • Isle of Man

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SALVAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2016
N3LNBST (Boerse-Stuttgart)YesOrdinary SharesDEEURMar 2016
SLVA.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2016

Biography

SalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/06 23:02
End of Day Share Price2019/07/09 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.